Harpoon Therapeutics
在场
Harpoon Therapeutics 的所有者是 Merck.
是其中之一......
- Forbes Global 2000 (#162);
- Fortune 500 (#67);
- Fortune 500 Europe (#184);
- Global Fortune 500 (#229);
- Russell 3000;
- S&P 500;
- Stoxx 600;
- TOB Iconic 10,000.
Merck 是一家在股票代码 MRK (US) 下上市的公司。
Merck 在 32 个国家有直接业务。Merck 拥有 45家子公司，其中包括 EyeBio、Harpoon Therapeutics 和 Merck Animal Health。
他们在：
涉及Merck的并购和融资。
- Merck 已收购 EyeBio (公布2024七月14号).
- Merck has announced the acquisition of EyeBio (公布2024五月31号).
- Merck has announced the acquisition of Prometheus Biosciences (公布2023四月19号).
- Merck has announced the acquisition of Imago BioSciences (公布2023一月11号).
- 查看更多"Merck"相关新闻 Hide news involving Merck
高管
查看带有其 6 名主要高管的组织结构图
Harpoon Therapeutics 搜索最多的简介
- Chatan Charan, Senior Vice President, Product Development, Technic...
- Banmeet Anand, Senior Vice President, Translational Medicine
- Luke Walker, Chief Medical Officer
创建提醒
跟踪 Harpoon Therapeutics 的高管变动
生物技术
Merck 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Chromocell的新名称是Channel Therapeutics Corporation。 (公布2024十一月22号).
- Enveda Biosciences 刚刚宣布为 130 筹款数百万美元。 (公布2024十一月22号).
- Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
生物技术 行业的其他推荐联系人
消息
Harpoon Therapeutics 的最新新闻稿
- Harpoon Therapeutics to Participate in the Cantor Virtual Global Healthcare Conference | Harpoon Therapeutics, Inc.
- Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences | Harpoon Therapeutics, Inc.
- Harpoon Therapeutics Names Karin Ann Thacker, M.Sc., VP Regulatory Affairs and Quality Assurance | Harpoon Therapeutics, Inc.
- Harpoon Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update | Harpoon Therapeutics, Inc.
- Harpoon Therapeutics Announces Changes to Board of Directors | Harpoon Therapeutics, Inc.
- Harpoon Therapeutics Updates Information for its Participation in Two Upcoming Virtual Conferences | Harpoon Therapeutics, Inc.
- Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences | Harpoon Therapeutics, Inc.
- Harpoon Therapeutics Presents Interim Phase 1 Data from an Ongoing Dose Escalation Trial for the PSMA-targeting TriTAC® HPN424 at the ASCO20 Virtual Scientific Program | Harpoon Therapeutics, Inc.
- Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma | Harpoon Therapeutics, Inc.
- Harpoon Therapeutics Appoints Two New Members to Its Board of Directors | Harpoon Therapeutics, Inc.
- View more press releases Close
通过电子邮件
